58 results about "Thromboelastography" patented technology

Device, method, and computer program product for determining a material parameter of a blood coagulation cascade based on parameters of light diffused at a biofluid sample. In one example, the biofluid sample includes a blood sample. Laser light scattered by the sample is collected by the optical system in reflection and / or transmission mode. An image of the sample in so collected light is formed, and data representing fluctuations of laser speckle intensity with is processed to derive numerical descriptors associated with blood coagulation and fibrinolysis. In a specific case, such numerical descriptors are derived based on temporal dynamic of a viscoelastic characteristic of the blood sample.

The invention relates to the field of blood detection, in particular to a detection method for evaluating the curative effect and the residual condition of heparin drugs. The heparin drugs mainly comprise heparin, low-molecular-weight heparin and some heparinoid drugs. The detection method mainly comprises steps as follows: heparinase, a freeze-drying protective agent and an adhesive are mixed, then a mixed reagent in appropriate proportion is prepared from an obtained mixture by the aid of a buffer solution, the mixed reagent is enveloped in a test-cup and subjected to freezing and vacuum pumping treatment, and a heparinase cup is obtained. The detection method has a plurality of advantages that the operation is simple, the guarantee period is long, the stability is good and the like. Theheparinase cup and a common cup (a blank sample cup) are put in a thrombelastogram, an anticoagulant and a chelating agent are added to the cups respectively, endogenously activated whole blood samples are added to the test-cups, and thromboelastography is started for detection; values R of starting time of blood clot formation in the heparinase cup and the common cup are compared, and whether heparin exists in the blood can be judged; if heparin exists, the value R of the starting time of blood clot formation in the heparinase cup is smaller than that of the starting time of blood clot formation in the common cup. The method is simple to operate, a detection result is good in repeatability, and the accuracy is high.

The invention discloses a platelet inhibition rate calculation method based on thromboelastography. The method comprises the steps that a blood sample is detected to acquire a thromboelastogram, wherein the thromboelastogram comprises the maximum coagulation intensity MAt curve, the minimum coagulation intensity MAf curve and the platelet coagulation curve f(t) of a coagulated blood sample; the coordinate axis of the curves of the thromboelastogram is transformed, the X axis is translated to the position of the symmetry axis of the three curves; the amplitude value of the detected coagulationintensity and the coagulation time value are integrated; the integral coagulation strength DIt of the maximum coagulation intensity MAt curve, the integral coagulation intensity DIf of the minimum coagulation intensity MAf curve and the integral coagulation intensity of the coagulation curve f(t) are calculated respectively; and the platelet inhibition rate BPI=(1-(DI-DIf) / (DIt-DIf))*100% is calculated. The acquired evaluation results are more accurate and can accurately reflect the actual state of platelet inhibition after the use of platelet inhibitory drugs.

The invention discloses a detection method for functions of platelets. The detection method is used for analyzing and evaluating the functions of the platelets and comprises platelet detection as follows: (1) carrying out platelet activated detection; (2) carrying out blood clotting factor activated detection; (3) carrying out platelet inhibited detection. The detection method is applicable to the platelet function determination of a thromboelastography by a clotting method, and a platelet function detection result is obtained through separately adding obtained platelet detection values in a detected blood sample and carrying out further calculation. According to the method, by adopting a platelet inhibitor, a detection value serves as a background control parameter in platelet function analysis, and thus, the detection result is more reliable. Compared with the former detection methods, the method has the advantages that expensive hemocoagulase is not required to be used, so that the detection cost is reduced, and the method is applicable to clinical popularization.

The invention discloses a quality control product which comprises a quality control product 1 and a quality control product 2, wherein the quality control product 1 comprises the following components:2-6 parts by weight of factor-rich goat plasma, 2-5 parts by weight of sheep serum and 1-4 parts by weight of fibrinogen mother liquor; the quality control product 2 comprises the following components: 1 to 4 parts by weight of factor-deficient sheep plasma, 5 to 10 parts by weight of sheep serum and 0. 3 to 2 parts by weight of the fibrinogen mother liquor, the fibrinogen mother liquor is prepared by dissolving fibrinogen in the sheep serum, wherein the mass percentage of the fibrinogen is 10%; clotting factor extraction is not needed in the preparation process of the thromboelastography instrument quality control product, preparation steps are simplified, operation is easy, cost is low, results are accurate, and stability is good; test results of the thromboelastography instrument quality control product basically meet that of a quality control product produced by already listed US Haemoscope company, the thromboelastography instrument quality control product can replace the qualitycontrol product produced by the already listed US Haemoscope company, and customer use cost is reduced.

The invention relates to a serum-free quality control material for a thromboelastography (TEG) and use of the serum-free quality control material. The serum-free quality control material is prepared from the following components by weight percent: 3.5-25% of acrylamide and methylene diacrylamide mother liquor (24 to 1), 0.1-1% of tetramethyl ethylenediamine (TEMED), 1-15% of persulfate and 0.01% of stabilizer; water is used as a solvent, and inorganic polymers with definite chemical compositions are used; the serum-free quality control is simple in production process and low in cost, can be stored at the room temperature, and is good in stability; by controlling the concentration and amount of a catalyst, the kinetic parameters of the blood can be well simulated in three states of hypocoagulability, hypercoagulability and normal blood coagulation; a user can use very low cost to achieve the test or correction of operating states of the instrument in the three states of hypocoagulability, hypercoagulability and normal blood coagulation every day, thus guaranteeing the stability and reliability of test data.